tiprankstipranks
Imunon (IMNN)
NASDAQ:IMNN

Imunon (IMNN) AI Stock Analysis

Compare
1,132 Followers

Top Page

IM

Imunon

(NASDAQ:IMNN)

42Neutral
Imunon's financial instability, characterized by negative revenue and high leverage, is a critical concern. While technical indicators show some bullish momentum, the valuation remains unattractive due to negative earnings. The positive clinical developments offer potential, but funding challenges need addressing to sustain progress.
Positive Factors
Clinical Trial Results
Improved overall survival hazard ratio and increased survival benefit have been shown with IMNN-001 treatment.
Cost Management
Imunon's cost-effective approach, including in-house manufacturing and competitive pricing, has allowed it to beat internal cost projections for the trial.
Regulatory Approval
Imunon has full FDA alignment for its OVATION 3 trial, which is a positive development for advancing their study.
Negative Factors
Funding Challenges
The company has sufficient funding to initiate the Phase 3 program though will need to raise additional capital in 2025.
Market Competition
The trial is set to enroll approximately 500 women with ovarian cancer and will be a broad trial including both BRCA+/HRD and BRCA-/HRP patients, indicating potential competition with other treatments targeting similar populations.

Imunon (IMNN) vs. S&P 500 (SPY)

Imunon Business Overview & Revenue Model

Company DescriptionImunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.
How the Company Makes MoneyImunon generates revenue primarily through the development and commercialization of its proprietary therapeutic and vaccine solutions. The company may engage in licensing agreements, where it partners with other pharmaceutical or biotechnology firms to co-develop or distribute its products, thereby earning licensing fees and royalties. Additionally, Imunon may receive funding from government grants or research collaborations, which contribute to its research and development efforts. By advancing its pipeline of candidates through clinical trials and achieving regulatory approvals, Imunon positions itself to earn revenue from product sales, either directly or through strategic partnerships.

Imunon Financial Statement Overview

Summary
Imunon faces significant financial challenges, including consistently negative revenue, profitability, and cash flow metrics. The high leverage and negative returns further exacerbate financial instability, requiring strategic restructuring to improve financial health.
Income Statement
10
Very Negative
Imunon has consistently reported zero or negative revenue over the past years. Gross profit margins are nonexistent, with significant net losses indicating severe profitability issues. EBIT and EBITDA margins are deeply negative, showing a lack of operational efficiency. There is no evidence of revenue growth, suggesting challenges in achieving market penetration or product commercialization.
Balance Sheet
25
Negative
The company exhibits a relatively high debt-to-equity ratio, indicating reliance on debt financing. Return on Equity (ROE) is negative, reflecting ongoing net losses. The equity ratio shows some equity presence but is overshadowed by continuous financial strain. The balance sheet stability is questionable due to high leverage and negative equity returns.
Cash Flow
20
Very Negative
Operating cash flow is consistently negative, reflecting poor cash generation from operations. Free cash flow is also negative, indicating insufficient cash to cover capital expenditures. Despite some positive financing and investing cash flow activities, the company's overall cash flow position is weak, raising concerns about liquidity and future operational funding.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
0.000.00500.00K500.00K500.00K
Gross Profit
0.00-720.00K-231.63K-202.92K-10.84M
EBIT
-19.13B-21.03M-24.92M-21.01M-18.49M
EBITDA
-19.13B-19.88M-31.71M-20.88M-21.30M
Net Income Common Stockholders
-18.62B-19.51M-35.90M-20.77M-21.48M
Balance SheetCash, Cash Equivalents and Short-Term Investments
5.87M15.70M32.88M49.50M17.16M
Total Assets
9.72M21.92M43.98M74.05M37.53M
Total Debt
1.14B1.62M6.27M6.63M6.19M
Net Debt
1.14B-4.21M-5.23M-12.95M-10.97M
Total Liabilities
5.47M8.53M14.65M18.25M18.92M
Stockholders Equity
4.24B13.39M29.33M55.80M18.61M
Cash FlowFree Cash Flow
-18.88B-19.47M-23.40M-16.54M-15.64M
Operating Cash Flow
-18.85B-19.02M-23.13M-16.22M-15.62M
Investing Cash Flow
9.83B11.01M8.32M-30.12M7.92M
Financing Cash Flow
9.06B-3.64M6.72M54.77M17.98M

Imunon Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.05
Price Trends
50DMA
0.92
Positive
100DMA
0.88
Positive
200DMA
1.01
Positive
Market Momentum
MACD
0.05
Negative
RSI
60.60
Neutral
STOCH
63.36
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMNN, the sentiment is Positive. The current price of 1.05 is above the 20-day moving average (MA) of 0.96, above the 50-day MA of 0.92, and above the 200-day MA of 1.01, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 60.60 is Neutral, neither overbought nor oversold. The STOCH value of 63.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IMNN.

Imunon Risk Analysis

Imunon disclosed 44 risk factors in its most recent earnings report. Imunon reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Imunon Peers Comparison

Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
62
Neutral
$682.21M-37.72%-3.08%
48
Neutral
$6.86B1.11-50.22%2.47%16.71%1.53%
42
Neutral
$15.42M-211.21%24.16%
36
Underperform
$98.19M-424.44%51.02%
32
Underperform
$69.25M-23.98%-19.93%
30
Underperform
$65.31M78.44%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IMNN
Imunon
1.05
-0.34
-24.46%
SRNE
Sorrento Therapeutics
0.01
0.00
0.00%
IMUX
Immunic
1.11
-0.12
-9.76%
EPIX
ESSA Pharma
1.58
-6.58
-80.64%
AVXL
Anavex Life Sciences
8.56
4.08
91.07%
BYSI
Beyondspring
1.57
-1.03
-39.62%

Imunon Earnings Call Summary

Earnings Call Date: Feb 27, 2025 | % Change Since: 31.25% | Next Earnings Date: May 19, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in clinical trials and potential for accelerated approval of Imunon-001, alongside strong safety data. However, concerns about cash runway and funding needs were also discussed, indicating a need for careful financial management.
Highlights
Positive Results from OVATION 2 Study
Imunon, Inc. announced positive results from the Phase 2 OVATION 2 study, showing an improvement in median overall survival of 13 months compared to the standard of care in ovarian cancer patients.
Phase 3 Study Initiation
The company is on track to initiate the pivotal Phase 3 OVATION 3 study in March 2025, following supportive feedback from the FDA.
Translational Data from OVATION 2
New translational data indicates a strong dose response in IL-12 levels, with 100 mg/m^2 showing about a 20% increase compared to the previous highest dose studied, demonstrating the potential for effective treatment with a favorable safety profile.
Potential for Accelerated Approval
The company is optimistic about the potential for accelerated approval based on the strength of OVATION 2 data, particularly in subgroups such as women receiving PARP inhibitors.
Strong Safety Profile
Imunon-001 demonstrates a favorable benefit-risk profile, with no elevation of immune-related adverse events or cytokine release syndrome observed.
Lowlights
Cash Runway and Funding Challenges
Imunon, Inc. has a cash runway extending only into late June 2025, raising concerns about the need for additional financing and partnerships to support ongoing trials.
Research and Development Expenses
Research and development expenses increased slightly to $11.6 million in 2024, primarily due to increased clinical spend related to OVATION 2 and startup costs for OVATION 3.
Company Guidance
In the recent conference call, Imunon, Inc. provided guidance on several key metrics related to their progress and future plans. They highlighted the success of their Phase 2 OVATION 2 study for Imunon-001 in treating advanced ovarian cancer, showing a median overall survival improvement from 11 months to 13 months over standard care. This compelling data has led to FDA agreement to initiate a pivotal Phase 3 study, with treatment expected to start in March 2025. The company is focused on an aggressive timeline for commercialization, supported by promising translational data and a favorable benefit-risk profile. Imunon-001 showed a strong dose response in IL-12 levels, maintaining low systemic levels to avoid toxicity. Financially, Imunon, Inc. reported a net loss of $18.6 million for 2024 with a cash runway extending into the second quarter of 2025 and is actively seeking financing and partnerships to support its strategic objectives.

Imunon Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
Imunon Appoints Dr. Douglas Faller as CMO
Positive
Feb 10, 2025

On February 18, 2025, IMUNON appointed Dr. Douglas Faller as Chief Medical Officer to lead the company’s clinical strategy, including advancing its lead program IMNN-001 into a Phase 3 trial for advanced ovarian cancer. Dr. Faller brings over 30 years of experience in oncology and immunology, and his appointment is expected to bolster IMUNON’s efforts in progressing its pipeline of non-viral DNA-based immunotherapies, leveraging his expertise to drive clinical programs and potential commercialization.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.